Compare KG & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KG | RPID |
|---|---|---|
| Founded | N/A | 2006 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.3M | 84.8M |
| IPO Year | 2025 | 2021 |
| Metric | KG | RPID |
|---|---|---|
| Price | $5.19 | $1.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 37.7K | ★ 307.6K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1819.15 | 2.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $34,049,000.00 | $33,587,000.00 |
| Revenue This Year | N/A | $19.12 |
| Revenue Next Year | N/A | $18.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 785.08 | 19.74 |
| 52 Week Low | $4.82 | $1.08 |
| 52 Week High | $27.55 | $4.94 |
| Indicator | KG | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 36.33 | 25.73 |
| Support Level | N/A | N/A |
| Resistance Level | $12.02 | $2.18 |
| Average True Range (ATR) | 0.49 | 0.07 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 21.40 | 16.67 |
Kestrel Group Ltd specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers with two reportable segments: Program Services and Legacy Reinsurance. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.